Premixed insulin preparations and glycaemic control in type 1 diabetes mellitus
Related Experiment Video
Updated: Oct 18, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
1University College Dublin.
Abstract:
The role of premixed insulin preparations in Type 1 DM remains unresolved. The degree of glycaemic control achieved with the use of premixed insulin preparations in an unselected group of subjects with Type 1 DM has not previously been reported. We abstracted and reviewed data on 600 subjects with Type 1 diabetes mellitus in our computer data base. 134 (23%) were taking two injections of premixed insulin daily. In these subjects glycaemic control as assessed by the most recent HbA1c measurement was 7.6 +/- 0.1% vs 7.4 +/- 0.1% in those subjects on separate insulins, p = N.S. In those subjects aged < 35 years, 62/220 (28%) used premixed insulin. HbA1c was higher in those on premixed insulin 7.8 +/- 0.2% and 7.2 +/- 0.1%, p < 0.05. This difference in HbA1c was seen only in those subjects with diabetes duration of 3 to 8 years (n = 78) where HbA1c was higher in those subjects on premixed insulin, 8.4 +/- 0.5% versus 6.9 +/- 0.2%, p < 0.01. In subjects aged > 35 years, 74/318 (23%) used premixed insulin. HbA1c did not differ between those using premixed insulin and those using separate insulin preparations, 7.5 +/- 0.2% and 7.5 +/- 0.1% respectively. We conclude that use of premixed insulin preparations achieved a similar level of glycaemic control as use of individual insulin preparations with the exception of patients aged less than 35 years who were 3 to 8 years following diagnosis. The relatively good glycaemic control achieved may make these preparations a useful alternative to multiple injection therapy for many patients with Type 1 DM.
Related Concept Videos
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into rapid-acting...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Oral Hypoglycemic Agents: Glinides
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...